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Suhag H. Parikh,1 Adam Mendizabal,2 Paul L. Martin,1 Vinod K. Prasad,1 Paul Szabolcs,1
Timothy A. Driscoll,1 Joanne Kurtzberg1Myelodysplastic syndromes (MDS) respond poorly to chemotherapy. Between 1995 and 2006, 23 pediatric pa-
tients with MDS were transplanted with unrelated donor umbilical cord blood (UUCB) at our center. The me-
dian agewas 11.1 years (range: 1.1-19.7),medianweightwas 38.6 kg (range: 9.6-62.6), 61%of patientsweremale,
andmedian time fromdiagnosis to transplantwas 6.6months (range: 2.0-61.4). Patientswere followed for ame-
dian of 5.3 years (range: 1.6-12.4 years) posttransplant. MDS stagewas refractory anemia (RA) in 12, refractory
anemiawith excess blasts (RAEB) in 8, and refractory anemiawith excess blasts in transformation (RAEB-T) in 3
patients; 18 (78%) patients had primaryMDS. Monosomy 7was present in 17(74%) patients. Patients with acute
myelogenous leukemia (AML) were excluded. Preparative regimen was total body irradiation (TBI) based in 18
(78%) patients. Graft-versus-host-disease (GVHD) prophylaxis was cyclosporine (CsA)/steroids (19 patients)
or CsA/mycophenolate mofetil (MMF; 4 patients). Grafts were HLA matched at Class I (A and B) at low reso-
lution and Class II (DRB1) at the allelic level, resulting in 16 (70%) 4/6 and 7 (30%) 5/6 matched transplants. The
grafts contained amedian of 4.0 107 (range: 1.7-12.6) total nucleated cells (TNC)/kg precryopreservation; 3.6
 107 (range: 1.0-12.0) TNC/kg and 1.7  105 (range: 0.2-28.5) CD341 cells/kg were infused. Cumulative in-
cidence of neutrophil engraftment (absolute neutrophil count [ANC] .500/mL) at day 42 and day 100 was
73.9% (95% confidence interval [CI] 55.1%-92.7%) and 91.3% (95% CI 71.3%-100.0%) respectively, and that
of platelet engraftment (50 K) at 180 days was 69.6% (95% CI 49.8%-89.4%). Three patients had graft failure
whereas 3 patients (13%) engrafted slowly (after day 42). Three patients developed acute GVHD (aGVHD)
grades II-IV with a cumulative incidence at 100 days of 13% (95% CI 0.0%-27.1.0%). Four patients relapsed
with a cumulative incidence of relapse at 3 years of 13.0% (95% CI 0.0%-27.1%). Cumulative incidence of non-
relapse mortality (NRM) at 1 year was 27% (95% CI 8.0%-46.0%). Ten patients died: 3 graft failure, 4 relapse, 2
infections (1 adenovirus, 1 toxoplasmosis), and 1 Epstein-Barr virus (EBV) lymphoproliferative disorder. Prob-
abilities of event-free survival (EFS) at 1 and 3 yearswere 69.6% (95%CI 46.6%-84.2%) and 60.9% (95%CI 38.3%-
77.4%), respectively. Factors associated with better EFS were age#11 years (P5 .05) and weight#38 kg (P5
.03). These results, especially in younger patients with monosomy 7 positive MDS, are equivalent to published
matched allogeneic bone marrow data. UUCB should be actively considered for pediatric MDS patients lacking
matched related or unrelated adult donors.
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Myelodysplastic syndromes (MDS) are heteroge-
neous disorders of hematopoietic stem cells, character-
ized by bone marrow (BM) dysplasia, ineffective
hematopoiesis leading to progressive cytopenias, and
a variable tendency to evolve into acute myelogenous
leukemia (AML).MDS ismore commonly seen in adults
where the incidence ranges from 3.5 to 12.6 cases/
100,000 population/year [1]. The incidence in adults in-
creases with age, and has been reported to be as high as
89 cases/100,000 beyond 80 years of age [2]. Cytoge-
netic abnormalities, including monosomy 5 and/or 7,
Biol Blood Marrow Transplant 15:948-955, 2009 949Unrelated Cord Blood Transplant in Pediatric MDSare seen in 40% to 70% of patients with primary MDS
and in 95% of patients with secondary MDS [3,4].
ChildhoodMDS differs from adultMDS in several
ways. MDS is more rare in children with an overall
incidence of approximately 3 to 4million [5,6]. The bi-
ology of MDS also differs in children. Not only are cy-
togenetic abnormalities far more common in children,
but the type of abnormalities tend to differ, with
monosomy 7 being more common in childhood
MDS and 5q- more common in adults. The Interna-
tional Prognostic Scoring System (IPSS), which uti-
lizes biologic parameters such as blast percentage,
complexity of cytogenetics, and degree of cytopenias,
and is useful in risk stratification in adult MDS pa-
tients, appears to be of limited value in guiding pediat-
ric MDS therapy, again underscoring the biologic
differences [7]. Treatment approaches are quite differ-
ent in childhoodMDS.The intent of treatment in chil-
dren with MDS is cure, as opposed to adults, where
palliation is often the most feasible approach. Even
though spontaneous remissions of MDS with mono-
somy 7 have been reported, these are rare and do not
preclude initiation of therapy with a curative intent
[8]. Intensive chemotherapy, similar to treatment in
patients with newly diagnosed AML, can induce re-
missions in 15% to 60% of patients, but these remis-
sions are not durable, resulting in high relapse rates
and overall survival (OS) of\30% [9-11]. Autologous
stem cell transplant (SCT) after high-dose chemother-
apy is also associated with a high relapse rate. Alloge-
neic SCT, using bone marrow (BM) or other
hematopoietic stem cell (HSC) sources, offers the
best chance for cure with long-term survival in approx-
imately half to two-thirds of patients [12-15].
More than half of MDS patients in need of SCT are
unable to find a suitably HLA matched related or unre-
lated living donor [16]. For such patients, partially
mismatched unrelated donor umbilical cord blood
(UUCB), which has been established as an alternative
source of stem cells for allogeneic transplantation for a
variety of malignant and nonmalignant disorders, may
be a potential source of graft. There is very limited data
on outcomes of UUCB transplantation in pediatric pa-
tients with MDS. We now describe outcomes of this
therapy in 23 pediatric patients with MDS with or with-
out monosomy 7 treated at a single institution.MATERIALS AND METHODS
Patients
We conducted a retrospective analysis of all con-
secutive patients with MDS who underwent hemato-
poietic stem cell transplantation (HSCT) at the
Pediatric Blood andMarrowTransplantationProgram
of Duke University Medical Center between 1995 and
August 2006. Data were analyzed as of April 25, 2008.Subsets of these patients were included in an abstract at
the 2008 American Society of Hematology annual
meeting [17] and in the COBLT malignancy cohort
[18]. Patients were classified according to the modified
WHO classification scheme suggested by Hasle et al.
[19]. The highest blast percentage during the period
from diagnosis of MDS to transplant was used to clas-
sify patients by the above-mentioned classification.
Patients who were\20 years of age at the time of
transplant were included if they received UUCB
transplant after myeloablative (MA) conditioning reg-
imen, had not had a previous transplant, and did not
have Fanconi anemia (FA), Down syndrome, or other
constitutional BM failure disorders. Juvenile myelo-
monocytic leukemia (JMML) cases and patients with
MDS who evolved to frank AML prior to transplant
were excluded.
Informed consent was obtained from the parent or
legal guardian of all patients prior to initiating MA
conditioning therapy.
Donor Selection
Grafts were matched at HLA Class I (A and B) at
low-resolution and HLA Class II (DRB1) at the allelic
level. Grafts were obtained from 6 public cord blood
banks in the United States (NYBC, Duke, ARC,
UCLA, Stemcyte, ITxM).
Preparative Regimen and graft-versus-host
disease (GVHD) Prophylaxis
AnMApreparative regimenwas used in all patients.
Eighteen patients were treated with a total body irradi-
ation (TBI)-based regimen (TBI/cyclophosphamide
[Cy]/antithymocyte globulin [ATG] in 8 patients,
TBI/melphalan [Mel]/ATG in 10 patients) and 5 pa-
tients received a busulfan (Bu)-containing, chemother-
apy-based regimen (Bu/Mel/ATG in 2 patients,
fludarabine [Flu]/Bu/Mel/ATG in 1 patient, Rituxi-
mab/Flu/Bu/Mel/ATG in 1 patient, and Bu/Cy/ATG
in 1 patient). First-dose Bu pharmacokinetics was ob-
tained in all patients and used to adjust the steady-state
concentration (Css) to 600 to 900 ng/mL over the dos-
ing period. GVHDprophylaxis consisted of cyclospor-
ine (CsA) with methylprednisolone in 19 patients and
CsA with mycophenolate mofetil (MMF) in 4 patients.
Supportive Care
All patients were hospitalized in the Pediatric bone
marrow transplant (BMT) unit ofDukeUniversityMed-
icalCenter andnursed in reverse isolationunder high-en-
ergy particulate air filtration and positive-pressure
ventilation. Patients were treated with broad-spectrum
antibiotics, starting with the first episode of neutropenic
fever and continued until neutropenia resolved. All pa-
tients received prophylaxis against Pneumocystis carinii,
fungal prophylaxis with fluconazole, amphotericin B, or
Table 1. Patient and Transplant Characteristics (N 5 23)
Variable Median Range
Age, years 11.1 1.1-19.7
Weight, kg 38.6 9.6-62.6
Follow-up, years 5.3 1.6-12.4
Time from diagnosis to transplant, months 6.6 2-61.4
Cellular characteristics
TNC pre-cryo (107/kg) 4.0 1.7-12.6
TNC infused (107/kg) 3.6 1.0-12.0
CD34+ (105/kg) 1.7 0.2-28.5
No. of patients %
Sex, male 14 61%
950 Biol Blood Marrow Transplant 15:948-955, 2009S. H. Parikh et al.voriconazole, and antiviral prophylaxis with acyclovir. All
patients received intravenous immunoglobulin (IVIG)
once aweek for thefirst 100days andonce amonth there-
after for the first year posttransplant. Low-dose continu-
ous .v. heparin infusion was employed from the initiation
of the preparative regimen through posttransplantation
day 28 for prophylaxis against veno-occlusive disease
(VOD).All patientswere supported as neededwith trans-
fusions of leukocyte-depleted, irradiated packed red
blood cells, and platelets. Filgrastim (Amgen, Thousand
Oaks, CA) was administered i.v. at 10 mg/kg/day from
day 0 until engraftment of donor cells and then tapered.Ethnic minorities 5 22%
CMV seropositive recipient 13 57%
Type of MDS
Primary MDS 18 78%
Therapy related-MDS 5 22%
Disease stage
RA 12 52%
RAEB 8 35%
RAEB-t 3 13%
Cytogenetics
Mono 7 17 74%
Other 2 9%
Normal 4 17%
Match characteristics
HLA mismatch
0 0 0
1 7 30%
2 16 70%
ABO matched 17 74%
Sex matched 11 48%
Ethnicity matched 15 65%
Conditioning
TBI based 18 78%
Busulfan based 5 22%
GVHD prophylaxis
CsA/methylprednisolone 19 83%
CsA/MMF 4 17%
CMV indicates cytomegalovirus; MDS, myleodysplastic syndromes; RA,
refractory anemia; RAEB, refractory anemia with excess blasts; RAEB-T,
refractory anemia with excess blasts in transformation; TBI, total body
irradiation; GVHD, graft-versus-host disease; CsA, cyclosporine; MMF,
myeophenolate mofetil.Statistical Methods
Neutrophil engraftment was defined as the first of 3
consecutive days of absolute neutrophil count (ANC)
.500/mL along with evidence of .90% donor chime-
rism.Donor chimerismwas assessed usingHLA, fluores-
cein in situ hybridization (FISH) or restriction fragment-
length polymorphism (RFLP) techniques. Platelet en-
graftmentwas defined as the first day of achieving platelet
count of 50 K/mL without receiving transfusion in the
previous 7 days. Primary graft failure was defined as
lack of donor cell chimerism by day 42 posttransplant
along with failure to achieve ANC.500/mL or if the pa-
tient died after day 14 without evidence of ANC .500
with or without donor cell chimerism. Delayed engraft-
ment was defined as evidence of donor cell chimerism
by day 42, but achievingANC.500/mLafter day 42.Re-
lapse was defined as the recurrence of previous cytoge-
netic marker, and/or morphologic evidence of MDS or
AML. Acute and chronic GVHD (aGVHD, cGVHD)
were scored by conventional criteria [20,21]. The proba-
bilities of neutrophil and platelet engraftment, aGVHD
and cGVHD, and relapse were estimated for all patients
transplanted surviving past 14 days using the cumulative-
incidence-function method [22].
OS was calculated from the date of transplant to
the date of death or date of last follow-up using the
Kaplan-Meier estimator [23], and the differences
were compared using log-rank statistics [24]. Cox pro-
portional hazards regression was used to create explor-
atory prognostic models with multiple variables [25].
Multivariate models were then constructed using
backward stepwise selection. Variables considered for
the model were those with a P value of .20 or less in
the univariate analysis. Variables with a value of P\
.05 were considered statistically significant and in-
cluded in the final model. All variables met the propor-
tional hazards assumption. Results were expressed as
hazard ratios, which compare the relative rate of event
occurrence between covariate categories. Baseline var-
iables considered include age at transplant, recipient
sex, donor sex, sex mismatch, type of MDS (primary
or secondary to therapy), disease stage, cell dose—total
nucleated cells (TNC) cryopreserved and reinfused,CD341 reinfused, HLA match, recipient race, donor
race, ABOmismatch recipient weight, time from diag-
nosis to transplant, karyotype, TBI, and Mel condi-
tioning regimen, and whether the recipient received
chemotherapy prior to transplant. All P values were 2
sided. The same analyses were carried out on event-
free survival (EFS), which was calculated from the
date of transplant to the date of event—death, relapse,
or graft failure; and on time to engraftment, which in-
cluded delayed engraftment. Analyses were completed
using the SAS system version 8.2, and R version 2.6.0.
(SAS Institute, Cary, NC).RESULTS
Patients
Twenty-three patients were enrolled on this study.
All patientswere transplantedwith unrelatedUCBunits
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Figure 1. (A) Cumulative incidence of neutrophil engraftment. (B) Cumulative incidence of platelet engraftment 50K. (C) Cumulative incidence of
aGVHD II-IV. (D) Cumulative incidence of cGVHD.
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are shown in Table 1. Briefly, 14 patients (61%) were
male, and 5patients (22%)belonged to racialminorities.
Median weight at the time of transplant was 38.6 kg
(range: 9.6-62.6 kg). Median ages at diagnosis of MDS
and transplant were 9.6 years (range: 0.6-19.1 years)
and 11.1 years (range: 1.1-19.7 years), respectively. Me-
dian time from the diagnosis of MDS to transplant was
6.6 months. Eighteen (78%) patients had primary
MDS, whereas the remaining 5 (22%) had therapy-re-
lated MDS. Disease stage was refractory anemia (RA)
in 12 (52%) patients, refractory anemia with excess
blasts in transformation (RAEB) in 8 (35%) patients,Table 2. Causes of Death
Causes of Death Primary Secondary
Relapse 4
Graft failure 3
Infection 2
EBV LPD 1 1
MSOF 4
EBV LPD indicates Epstein Barr Virus associated lymphoproliferative
disease; MSOF, multisystem organ failure.and refractory anemia with excess blasts in transforma-
tion-transformedRAEB-T in 3 (13%) patients. Ten pa-
tients received therapy within 12 months of transplant,
which consistedof cytotoxic chemotherapy in5patients,
immunosuppressive therapy (with CsA containing regi-
mens) in 4 patients, and amifostine/erythropoietin in 1
patient. Thirteen (57%) patients were cytomegalovirus
(CMV) seropositive prior to transplant.
Cytogenetics
Karyotypes in abnormal cells were normal in 4
(17%) patients, showed monosomy 7 in 17 (74%) pa-
tients, trisomy 8 in 1 patient, and t(2,3) with rearrange-
ment in chromosome 5 in 1 patient. Four patients with
monosomy 7 had additional complex cytogenetic ab-
normalities.
Donors
All patients received single umbilical cord blood
(UCB) grafts, except 1 patient who received double
UCB grafts. All 23 patients received partially mis-
matched graft: 7 (30%) from a 5/6 and 16 (69%) from
Survival At 1 Year: 69.6% (95% CI, 46.6%, 84.2%)
Survival At 3 Years: 59.2% (95% CI, 35.9%, 76.5%)
Overall survival
23 16 12 11 9 8 7 6 6 4 2 1 1
Number at risk
Survival At 1 Year: 69.6% (95% CI, 46.6%, 84.2%)
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Figure 2. (A) Kaplan-Meier estimates of OS. (B) Kaplan-Meier estimates of MDS-free survival.
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of 4.0  107 (range: 1.7-12.6) nucleated cells/kg based
on precryopreservation count. The median reinfused
TNC dose was 3.6  107cells/kg (range: 1.0-12.0)
and contained a median CD 341 cell dose of 1.7 
105/kg (range: 0.2-28.5). The grafts were ABO
matched in 17 (74%) patients, sex matched in 11
(48%) patients, ethnicitymatched in 15 (65%) patients.
Engraftment
By day 42, 17 of the 23 engrafted with donor cells.
Three additional patients engrafted after day 42 at
days 48, 56, and 104. Of the 20 engrafting patients,
the median time to neutrophil engraftment (ANC
.500/mL)was 26days (range: 11-104days).Cumulative
incidences of neutrophil engraftment at day 42 and day
100 were 73.9% (95% confidence interval [CI] 55.1%-
92.7%) and 91.3% (95% CI 73.1%-100.0%), respec-
tively (Figure 1A). Three patients experienced primary
graft failure and subsequently died of transplantation-
related complications, despite salvage transplant in 2
of these 3 patients. Seventeen patients achieved platelet
engraftment in amedian of 72days (range: 41-205days).
Cumulative incidence of platelet engraftment at day 100
was 60.9% (95% CI 40.1%-81.7%) and at day 180 was
69.6% (95% CI 49.8%-89.4%) (Figure 1B). No signif-
icant predictors of engraftment or graft failure were
identified from the variable set tested.
GVHD
aGVHD (grades I-IV) was seen in 11 patients.
Eight patients experienced grade I aGVHD, 2 had
grade II, and 1 experienced grade III. LimitedcGVHD was seen in 7 patients, 6 of whom previously
had aGVHD. Of these 6 patients, 5 had grade I prior
aGVHD, and 1 had grade III prior aGVHD. The me-
dian time to the onset of cGVHDwas 301 days (range:
152-363). Extensive cGVHD did not occur in any pa-
tient. The 1-year cumulative incidence of grade II-IV
aGVHD, grade III-IV aGVHD, and cGVHD (all lim-
ited) were 13.0% (95% CI 0.0%-27.1%), 4.3% (95%
CI 0.0%-12.9%), and 32.1% (95% CI 11.7%-
52.5%), respectively (Figure 1C, 1D).
Relapse
Four patients engrafted with donor cells and subse-
quently experienced a relapse of theirMDS in amedian
of 567.5 days posttransplant (range: 76-1728 days).
The cumulative risk of relapse at 3 years was 13%
(95% CI 0.0% -27.1%). All relapses occurred in host
cells.
Nonrelapse mortality (NRM)
Cumulative risk of NRM at 1 year was 27.0%
(95% CI 8.0%-46.0%). Of the 23 patients, 10 died at
a median of 173.5 (range: 43-2738) days posttrans-
plant. Causes of death (Table 2) were graft failure,
relapse, infection, Epstein-Barr virus (EBV) lympho-
proliferative disease, and multisystem organ failure
(MSOF).
OS and EFS
OS for all patients at 1 year and 3 years were 69.6%
(95% CI 46.6%-84.2%) and 59.2% (95% CI 35.9-
76.5), respectively (Figure 2A). EFS was 69.6% (95%
CI 46.6%-84.2%) at 1 year and 60.9% (95% CI
Table 3. Univariate and Multivariate Analysis: Impact of Age and Weight on Event-Free Survival (EFS)
Event-Free Survival
Event-Free Survival
Probability Univariate Analysis
Final Multivariate Model
(Includes Only Significant Variables)
Variable At 3 Years (95% CI) Hazard Ratio (95% CI) P-Value Hazard Ratio (95% CI) P-Value Favorable Factors
All patients 60.9% (38.3%-77.4%) — — —
Age
#11 Years 81.8% (44.7%-95.1%) 1.00
>11 Years 41.7% (15.2%-66.5%) 4.74 (0.99-22.51) .05
Recipient Weight (kg) Weight #38 kg
#38 90.9% (50.8%-98.7%) 1.00 1.00
>38 33.0% (10.3%-58.8%) 5.61 (1.16-27.11) .03 5.61 (1.16-27.11) .03
CI indicates confidence interval.
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difference in outcomes between patients with primary
or secondaryMDS. Monosomy 7 did not influence the
outcome. In univariate analysis, age (P 5 .04) and
weight (P 5 .02) were statistically associated with
OS. Similarly, age (P 5 .05) and weight (P 5 .03)
were the only variables that demonstrated a significant
influence on EFS survival. Variables considered in an
exploratory multivariate analysis were age, weight,
type of MDS (primary or secondary), cell dose 
107/kg cryopreserved, cell dose 107/kg reinfused. In-
teractions were also investigated; however, none were
found to be significant when the main effects remained
in the model. In multivariate analyses only weight re-
mained significant for both OS and EFS (Table 3).DISCUSSION
Outcomes of pediatric patients with MDS treated
with conventional chemotherapy therapy are poor
[9,10]. Allogeneic HSCT currently offers the best
chance of cure and long-term survival [1,10]. We re-
port outcomes of pediatric patients with MDS treated
with UUCB transplant at a single institution. UCB
was used as the source of graft in these patients because
of unavailability of a suitably matched living related or
unrelated BM donor. We excluded patients with
JMML and MDS secondary to constitutional disor-
ders such as FA, Kostmann’s, etc., because of growing
evidence that these disorders are biologically distinct
[11,19]. Twenty-three pediatric patients withMDS re-
ceived UUCB grafts, all of which were mismatched at
either 1 or 2 HLA loci. All patients received MA pre-
parative regimen that was predominantly TBI based.
EFS was 61% at 3 years, with a median follow-up of
5.3 years. Primary graft failure and relapse were the
major causes of treatment failure and death. Recipient
weight (#38 kg) was associated with a favorable out-
come inmultivariate analysis. Factors such as pretrans-
plant therapy, TBI containing preparative regimens,
graft cell dose, HLA matching, ABOmismatching, re-
cipient pretransplant CMV serostatus did not influ-
ence OS or disease-free survival (DFS). Althoughtthe impact of weight is consistent with the cord blood
experience in other diseases, the lack of impact from
the remaining factors may well be the result of the
small sample size [26]. Patients in the present study re-
ceived grafts with a relatively high cell dose (median
precryopreservation cell dose of 4  107 TNC/kg),
which combined with small sample size may have
masked the effect of cell dose. No obvious risk factors
were found to be associated with the poor outcome in
older patients (.11 years) noted only in univariate
analysis.
Data from several single institution and multicen-
ter registry studies, reflectingmostly outcomes of adult
MDS patients undergoing allogeneic BM transplanta-
tion, indicate approximate rates for EFS of 30% to
40%, relapse rate of 20%, and NRM of 40% to 45%
[1]. There is relatively limited data on allogeneic trans-
plantation in the pediatric population with MDS and
involves BN as the predominant stem cell source (sum-
marized in Table 4). In pediatric studies, the overall
rates of EFShas ranged between 15%and 69%with re-
lapse rates of 14% and 26%. Treatment-related mor-
tality (TRM) was high, as observed in the adult
studies. Our results compare favorably to these re-
ported studies. The cumulative incidence of engraft-
ment of 91% and median time to engraftment of
26 days are comparable to previously reported unre-
lated cord blood transplantation registry data from
New York Blood Center [27] and slightly better than
that reported from European registries [26]. Interest-
ingly, 3 patients engrafted after day 42, one of the pa-
tients engrafting after day 100. Although this could
be a result of a host of factors, one can speculate that
the biology of MDS includes an abnormal BM micro-
environment, which contributed to delayed engraft-
ment of the healthy donor cells. In multivariate
analysis, engraftment was not affected by any of the var-
iables tested including cell dose, HLA matching, con-
ditioning regimen and pretransplant chemotherapy.
Cumulative incidence of aGVHD II-IV, limited
cGVHD, and extensive cGVHD at 1 year in our series
was 13%, 32.1%, and 0%, respectively. The incidence
of aGVHD was lower compared to that described for
BMT patients despite the greater degree of HLA
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tients had extensive cGVHD. Yet, the incidence of re-
lapse (13%) in our series was not higher than previous
studies. This is consistent with previously reported re-
sults using cord blood as a graft source for unrelated
donor transplantation [29,30].
TRMorNRMhas ranged from 21% to 54% in the
larger series involving pediatric patients. In our series,
the 1 year TRM was 27%, which is comparable to
these studies.
The incidence of monosomy 7 in our series is
higher than that in the published data. This could be
a result of referral bias, or reflect the heterogeneity
of the disease. Presence of monosomy 7 did not have
a negative impact on the outcome of patients in our se-
ries, similar to the experience of several recent studies,
which have suggested that monosomy 7 may not be an
independent prognostic factor for patients with pedi-
atric MDS who undergo allogeneic transplant early
in the course of their disease [12,14].
Outcomes of patients with therapy-related MDS
were comparable to those for de novo MDS in this
series. Woodard et al. [31], in a recent report de-
scribed the outcomes of 38 children with therapy-re-
lated MDS and AML, and found the 3-year survival
(OS and EFS) to be 15.4% with the TRM of 60%,
suggesting that this category of patients have a poor
outcome probably because of increased cumulative
exposure to previous chemotherapy and/or radiother-
apy. The outcome of patients with therapy-related
MDS in this series is better, but the number of pa-
tients is too small to know if this is a real difference
overall. Nevertheless, TRM remains a major chal-
lenge in these patients and reduced-intensity condi-
tioning (RIC) regimens need to be studied. In fact,
a recent European Working Group (EWOG)-MDS
report illustrates the feasibility as well as excellent re-
sults of this approach using BM or peripheral blood
as graft source in low-risk pediatric patients with
RA without clonal abnormalities [32].
In conclusion, our single institution series of unre-
lated cord blood transplant in pediatric patients with
MDS demonstrates that unrelated cord blood trans-
plant is an effective and curative approach in these pa-
tients. The presence of monosomy 7 did not adversely
affect the outcome after transplantation. Graft failure
and relapse were the main causes of treatment failure.
Outcomes may be improved in the future by ap-
proaches to enhance engraftment of unrelated cord
blood grafts, approaches to decrease regimen related
toxicity (eg, employing RIC regimens) and/or imple-
mentation of newer agents in an attempt to decrease
relapse rates (eg, hypomethylating agents) prior to,
or as continuation of therapy after transplant in se-
lected patients. The outcomes are best in younger pa-
tients, and transplant is thus recommended early in the
course of the disease.
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